Year archive

Pentixapharm Holding AG — 2026 filings

All 12 regulatory filings released by Pentixapharm Holding AG (PTP) in 2026, sourced directly from the official regulator.

12 Filings

2026 Period

2026 filings (12)

Filing	Released	Lang
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Regulatory Filings	2026-05-11	English
Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Regulatory Filings	2026-05-07	English
Q1 statement / Q1 financial report 2026 Interim / Quarterly Report Q1 2026	2026-05-07	English
Annual financial report 2025 Annual Report FY 2025	2026-04-28	English
Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Board/Management Information	2026-03-31	English
Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026 Report Publication Announcement	2026-03-19	English
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024 Audit Report / Information FY 2024	2026-03-16	German
Report Publication Announcement 2026 Report Publication Announcement	2026-03-06	English
Hinweis auf Jahresfinanzbericht vom 01.01.2025 bis zum 31.12.2025 Report Publication Announcement	2026-03-06	German
Pentixapharm Receives FDA Study May Proceed Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program Regulatory Filings	2026-02-25	English
Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism Regulatory Filings	2026-02-05	English
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension Regulatory Filings	2026-01-07	English